PL421967A1 - Płynna forma podawania furaginy oraz sposób jej otrzymywania - Google Patents

Płynna forma podawania furaginy oraz sposób jej otrzymywania

Info

Publication number
PL421967A1
PL421967A1 PL421967A PL42196717A PL421967A1 PL 421967 A1 PL421967 A1 PL 421967A1 PL 421967 A PL421967 A PL 421967A PL 42196717 A PL42196717 A PL 42196717A PL 421967 A1 PL421967 A1 PL 421967A1
Authority
PL
Poland
Prior art keywords
furagin
administering
obtaining
furagine
fluid form
Prior art date
Application number
PL421967A
Other languages
English (en)
Other versions
PL236891B1 (pl
Inventor
Hanna WAHL
Marek DĄBROWA
Anna OSTROWSKA
Małgorzata DASZKIEWICZ
Małgorzata PARTEKA
Arkadiusz MADEJCZYK
Original Assignee
Aflofarm Farm Polska Spolka Z Ograniczona Odpowiedzialnoscia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aflofarm Farm Polska Spolka Z Ograniczona Odpowiedzialnoscia filed Critical Aflofarm Farm Polska Spolka Z Ograniczona Odpowiedzialnoscia
Priority to PL421967A priority Critical patent/PL236891B1/pl
Priority to PCT/PL2018/050026 priority patent/WO2018236236A1/en
Priority to RU2020101969A priority patent/RU2770041C2/ru
Priority to EP18819858.4A priority patent/EP3641729A4/en
Priority to UAA202000320A priority patent/UA126867C2/uk
Publication of PL421967A1 publication Critical patent/PL421967A1/pl
Publication of PL236891B1 publication Critical patent/PL236891B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Przedmiotem zgłoszenia jest płynna forma podawania furaginy charakteryzująca się tym, że zawiera furaginę w ilości od 0,10 g / 100 g do 5,04 g / 100 g, substancję słodzącą wybraną z grupy disacharydów, substancję stabilizującą zawiesinę, substancje konserwujące, substancje stabilizujące zawiesinę regulujących lepkość, substancję stabilizującą zawiesinę oraz powierzchniowo czynną, substancję masującą gorzki smak oraz wodę oczyszczoną jako rozpuszczalnik. Przedmiotem zgłoszenia jest też sposób przygotowania podawania płynnej formy furaginy.
PL421967A 2017-06-21 2017-06-21 Płynna forma podawania furazydyny oraz sposób jej otrzymywania PL236891B1 (pl)

Priority Applications (5)

Application Number Priority Date Filing Date Title
PL421967A PL236891B1 (pl) 2017-06-21 2017-06-21 Płynna forma podawania furazydyny oraz sposób jej otrzymywania
PCT/PL2018/050026 WO2018236236A1 (en) 2017-06-21 2018-06-19 Furazidin composition in the form of suspension and method for preparation thereof
RU2020101969A RU2770041C2 (ru) 2017-06-21 2018-06-19 Композиция фуразидина в форме суспензии и способ ее получения
EP18819858.4A EP3641729A4 (en) 2017-06-21 2018-06-19 COMPOSITION OF FURAZIDINE IN SUSPENSION FORM AND PROCESS FOR PREPARATION
UAA202000320A UA126867C2 (uk) 2017-06-21 2018-06-19 Композиція фуразидину у вигляді суспензії і спосіб її отримання

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL421967A PL236891B1 (pl) 2017-06-21 2017-06-21 Płynna forma podawania furazydyny oraz sposób jej otrzymywania

Publications (2)

Publication Number Publication Date
PL421967A1 true PL421967A1 (pl) 2019-01-02
PL236891B1 PL236891B1 (pl) 2021-02-22

Family

ID=64737767

Family Applications (1)

Application Number Title Priority Date Filing Date
PL421967A PL236891B1 (pl) 2017-06-21 2017-06-21 Płynna forma podawania furazydyny oraz sposób jej otrzymywania

Country Status (5)

Country Link
EP (1) EP3641729A4 (pl)
PL (1) PL236891B1 (pl)
RU (1) RU2770041C2 (pl)
UA (1) UA126867C2 (pl)
WO (1) WO2018236236A1 (pl)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1782587A1 (en) * 1989-03-10 1992-12-23 Lvovskij G Med Inst Composition for treating parodontitis
RU2583945C1 (ru) * 2015-05-13 2016-05-10 Федеральное государственное бюджетное учреждение науки Институт органического синтеза им. И.Я. Постовского Уральского отделения Российской академии наук (ИОС УрО РАН) Средство для местного лечения красного плоского лишая слизистой оболочки полости рта и способ лечения красного плоского лишая слизистой оболочки полости рта

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2103997C1 (ru) * 1995-04-19 1998-02-10 Акционерное общество закрытого типа "Гекта" Лекарственное средство для лечения заболеваний животных микробной этиологии, способ лечения желудочно-кишечных заболеваний животных микробной этиологии и способы лечения гинекологических заболеваний коров микробной этиологии
US6521270B1 (en) * 2001-06-11 2003-02-18 The Procter & Gamble Company Compositions comprising nitrofurantoin and uva ursi
PL234271B1 (pl) * 2016-10-10 2020-01-31 Centrum Badawczo Rozwojowe Novasome Spolka Z Ograniczona Odpowiedzialnoscia Doustna kompozycja farmaceutyczna zawierająca furazydynę w postaci zawiesiny oraz sposoby jej wytwarzania
RU2019110218A (ru) * 2016-10-10 2020-11-13 Фармацевтическое Предприятие Хасцо-Лек С.А. Новые композиции на основе фуразидина и способы их изготовления

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1782587A1 (en) * 1989-03-10 1992-12-23 Lvovskij G Med Inst Composition for treating parodontitis
RU2583945C1 (ru) * 2015-05-13 2016-05-10 Федеральное государственное бюджетное учреждение науки Институт органического синтеза им. И.Я. Постовского Уральского отделения Российской академии наук (ИОС УрО РАН) Средство для местного лечения красного плоского лишая слизистой оболочки полости рта и способ лечения красного плоского лишая слизистой оболочки полости рта

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PABERZA M. ET AL., "SOME ASPECTS OF THE EXCRETION OF FURAGIN WITH THE URINE OF 1-12 RABBITS", FARMATSIYA (MOSCOW RUSSIAN FEDERATION), 29(3), IN RUSSIAN (ABSTRAKT), 30 June 1980 (1980-06-30) *
TSAGAREISHVILI, G. V. ET AL., "STABILIZATION OF THE SUSPENSIONS OF 5-NITROFURAN 1-12 DERIVATIVES", IZVESTIYA AKADEMII NAUK GRUZINSKOI SSR, SERIYA KHIMICHESKAYA (1975), 1(2), IN RUSSIAN ABSTRACT, 1975 *

Also Published As

Publication number Publication date
EP3641729A4 (en) 2021-03-24
EP3641729A1 (en) 2020-04-29
RU2020101969A3 (pl) 2021-09-20
PL236891B1 (pl) 2021-02-22
RU2770041C2 (ru) 2022-04-14
RU2020101969A (ru) 2021-07-21
UA126867C2 (uk) 2023-02-15
WO2018236236A1 (en) 2018-12-27

Similar Documents

Publication Publication Date Title
MY197024A (en) Amylin analogues
PL3752510T3 (pl) Makrocykle jako modulatory mukowiscydozowego przezbłonowego regulatora przewodnictwa, ich kompozycje farmaceutyczne, ich zastosowanie w leczeniu mukowiscydozy oraz proces ich wytwarzania
PL3896064T3 (pl) Pochodne 4,6-diamino-chinolino-3-karbonitrylu jako modulatory cot w leczeniu choroby leśniowskiego-crohna i wrzodziejącego zapalenia jelita grubego
EP4309643A3 (en) Viscosity-reducing excipient compounds for protein formulations
SG10201808104RA (en) Cenicriviroc for the treatment of fibrosis
MX391748B (es) Formulaciones nutritivas que comprenden un aislado de proteina de guisante
EA201790223A1 (ru) Водный препарат, содержащий парацетамол и ибупрофен
HRP20191285T1 (hr) Predlijekovi karbidopa i l-dopa te njihova uporaba za liječenje parkinsonove bolesti
PH12017501674A1 (en) Amylin analogues
MX2017010544A (es) Metodos y composiciones para tratar la enfermedad del ojo seco y otros trastornos del ojo.
BR112017014994A2 (pt) formulação em pó nasal para o tratamento de hipoglicemia
MA46709A (fr) Traitement du cancer gastrique au moyen de polythérapies comprenant de l'oxaliplatine, du 5-fluoruracile (et de la leucovorine) et de l'irinotécan sous forme liposomale
MX2017007178A (es) Formulaciones liquidas estables de virus de vacuna.
BR112018008017A2 (pt) composição farmacêutica, método de preparação de composição farmacêutica líquida, kit farmacêutico, sistema de fornecimento de injeção
EP3399963C0 (en) GEL COMPOSITIONS FOR TRANSDERMAL DELIVERY FOR MAXIMIZING DRUG CONCENTRATION IN THE STRATUM CORNEUM AND SERUM AND METHODS OF USE THEREOF
MX2017015879A (es) Composiciones de hidroxipropil beta-ciclodextrina y metodos.
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
EA201990915A1 (ru) Новые модуляторы 5-гидрокситриптаминового рецептора 7 и способ их применения
EA202190281A1 (ru) Производные 3-((гетеро-)арил)-8-амино-2-оксо-1,3-диаза-спиро[4,5]декана
EA201792530A1 (ru) Пероральная композиция целекоксиба для лечения боли
AU2018282105A1 (en) Dosing of vibegron for treatment of overactive bladder
MX2017015202A (es) Formulaciones liquidas de celecoxib para administracion oral.
MX379253B (es) Formulaciones de oximetazolina estabilizadas y sus usos.
IL284263A (en) Treatment of hypercoagulability associated with Cushing's syndrome by administration of glucocorticoid receptor modulators
MY196333A (en) Intranasal Composition Comprising Betahistine